ICER evaluates patisiran and Tegsedi for amyloidosis

The Institute for Clinical and Economic Review (ICER) concluded that patisiran (ALN-TTR02) from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Tegsedi inotersen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) are not cost-effective treatments for hereditary transthyretin (TTR)-mediated amyloidosis based on analyst estimates.

In its draft evidence report published on July 20, ICER said the estimated incremental cost-effectiveness ratios for both therapies exceeded the commonly cited thresholds of $50,000-$150,000 per quality-adjusted life year (QALY) based on placeholder costs of $300,000 per year. For patisiran, the institute estimated incremental cost-effectiveness ratios of $830,000 per QALY based on heathcare sector perspectives and $850,000 per QALY based on modified societal perspectives. Tegsedi's estimated incremental cost-effectiveness ratios were about $1.2 million per QALY from both heathcare sector and modified societal perspectives...